Condition (MeSH)
Hepatitis, Animal
ClinicalTrials.gov lists 19 trials for Hepatitis, Animal or a narrower condition beneath it. U.S. Army Medical Research and Development Command has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
When did Hepatitis, Animal trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 4 |
| 2024 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2018 | 2 |
| 2015 | 1 |
| 2013 | 1 |
| 2011 | 1 |
| 2009 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hepatitis, Animal trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 8 |
How many Hepatitis, Animal trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Completed | 10 |
| Terminated | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hepatitis, Animal trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| U.S. Army Medical Research and Development Command | 4 |
| IDBiologics, Inc. | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
Which drugs are being tested for Hepatitis, Animal? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Rabies Vaccine | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| ChAdOx1 RVF | 3 |
| IDB-011 dose level 3 | 1 |
| IDB-011 dose level 5 | 1 |
| Nicardipine and Nipride | 1 |
| TSI-GSD 200 RVF Vaccine | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hepatitis, Animal trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Atrial fibrillation | 1 | 1 |
| Back surgery | 1 | 1 |
| Cyst exicision | 1 | 1 |
| Laproscopic surgery for RLQ pain | 1 | 1 |
| Left nephrectomy | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hepatitis, Animal? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Suppressive effect of modified arabinoxylan from rice bran (MGN-3) on D-galactosamine-induced IL-18 expression and hepatitis in rats. | Bioscience, biotechnology, and biochemistry | 2012 | Yes |
| The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. | Proceedings of the National Academy of Sciences of the United States of America | 2005 | Yes |
| Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. | Proceedings of the National Academy of Sciences of the United States of America | 1997 | Yes |
| T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. | The Journal of experimental medicine | 1994 | Yes |
| Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. | Gastroenterology | 1990 | Yes |
Showing 5 of 6 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.